Evogene Ltd. key statistics and ratios

In fiscal 2025, Evogene Ltd. had an operating margin of -364.2% and a current ratio of 4.54. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evogene Ltd.: financial ratios, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	25.8%	13.8%	15.9%	16.9%	55.6%	44.8%	17.5%	45.7%	50.0%	57.3%	−6.3%
Operating margin	−161.0%	−322.5%	−649.1%	<−999%	<−999%	<−999%	<−999%	<−999%	−745.5%	−337.2%	−364.2%
Net margin	−154.7%	−299.6%	−616.3%	<−999%	<−999%	<−999%	<−999%	<−999%	−800.8%	−295.6%	−220.2%
Free-cash-flow margin	−129.5%	−191.1%	−488.6%	−889.2%	<−999%	<−999%	<−999%	<−999%	−742.9%	−364.5%	−353.9%
Return on equity	−16.6%	−20.5%	−26.6%	−34.8%	−36.2%	−48.6%	−55.8%	−65.3%	−119.4%	—	—
Return on assets	—	−20.4%	−24.0%	−30.5%	−27.9%	−32.6%	−37.5%	−40.2%	−44.5%	−36.2%	−28.3%
Asset turnover	—	0.07	0.04	0.03	0.01	0.01	0.01	0.03	0.06	0.12	0.13
Current ratio	—	17.13	15.61	10.22	8.53	5.36	8.27	6.71	4.96	1.15	4.54
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—
Interest cover (operating income ÷ interest)	—	—	—	—	n/m	n/m	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	129.8%	250.8%	502.4%	840.6%	>999%	>999%	>999%	>999%	543.1%	224.3%	207.5%
Capital spending as % of revenue	18.0%	12.4%	17.5%	21.4%	119.5%	65.6%	91.1%	69.9%	19.3%	11.2%	3.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · December 31, 2025

What it owns · $20m

Short-term assets $16mLonger-term assets $4m

What it owes, and who funded it · $8m

Short-term liabilities $3mLonger-term liabilities $5mShareholders' equity $-0m

Short-term assets cover short-term liabilities $16m of assets due within a year against $3m of liabilities due within a year.
Short-term assets cover long-term liabilities $16m short-term assets against $5m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$14m against $183,000 of interest.

From Evogene Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: DBVT vs EVGN DYAI vs EVGN ALGS vs EVGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evogene Ltd.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evogene Ltd.